Table 4. Network meta-analysis of sustained virological response at week 24 after the end of treatment.
| Treatment | No. of subjects | No. of SVR12 | Pooled RR (95% CI) |
|---|---|---|---|
| DAA plus PR versus PR alone | |||
| PR | 375 | 187 | 1 |
| SMV plus PR | 1011 | 833 | 1.46 (1.22, 1.75) |
| SOF plus PR | 144 | 119 | 1.98 (1.24, 3.14) |
| DCV plus PR | 329 | 199 | 1.68 (1.14, 2.46) |
| Among DAA plus PR regimens | |||
| SOF plus PR vs SMV plus PR | - | - | 1.35 (0.82, 2.23) |
| DCV plus PR vs SMV plus PR | - | - | 1.15 (0.75, 1.76) |
| DCV plus PR vs SOF plus PR | - | - | 0.85 (0.46, 1.55) |
CI, confidence interval; DCV, daclatasvir; DAA, direct acting anti-viral agents; LDV, ledipasvir; PR, pegylated interferon-ribavirin; RR, risk ratio; SMV, simeprevir; SOF, sofosbuvir; SVR24, sustained virological response at week 24 after the end of treatment.